非小细胞肺癌诱导治疗前后骨骼肌体积、密度及FDG摄取的影像评估
回顾性分析88例初诊未治非小细胞肺癌患者诱导化疗前后的胸腰椎CT,其中42例有PET/CT。化疗后胸段骨骼肌体积减少3.3%(p=0.0005)、腰段减少2.6%(p=0.0101),密度<0 HU的肌肉比例增加7.9%(p<0.0001),骨骼肌FDG摄取增加10.4-31%(p<0.05),但无影像生物标志物与总生存相关。
要点
- 诱导化疗后胸段骨骼肌体积减少3.3%、腰段减少2.6%,脂肪组织未变。
- 密度<0 HU的骨骼肌比例增加7.9%,提示肌肉密度下降。
- 骨骼肌FDG摄取增加10.4-31%,但无影像标志物与总生存相关。
核心结论
- 常规胸部影像可测量身体成分变化;化疗期间骨骼肌体积与代谢发生改变,但本回顾性系列中未影响生存,需在前瞻性、良好对照研究中进一步验证。
研究设计与样本
- 回顾性研究,88例新诊断未治疗的非小细胞肺癌患者,诱导化疗前后行胸段及腰段CT测量骨骼肌体积与密度,其中42例亚组行PET/CT测量骨骼肌FDG摄取。
关键影像表现/征象
- 诱导化疗后胸段骨骼肌体积减少3.3%(p=0.0005),腰段减少2.6%(p=0.0101),脂肪组织保持不变。
- 密度<0 HU的骨骼肌比例增加7.9%(p<0.0001),反映骨骼肌密度下降。
- 骨骼肌FDG摄取增加10.4-31%(p<0.05)。
临床应用与阅片要点
- 常规胸部CT可系列评估骨骼肌体积与密度变化。
- PET/CT可评估骨骼肌FDG摄取变化。
- 本回顾性系列中无影像生物标志物与总生存相关。
局限性
- 本系列为回顾性研究。
- 原文结论指出需在前瞻性、良好对照研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To assess whether changes in body composition could be assessed serially using conventional thoracic computed tomography (CT) and positron-emission tomography (PET)/CT imaging in patients receiving induction chemotherapy for non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: CT-based skeletal muscle volume and density were measured retrospectively from thoracic and lumbar segment CT images from 88 patients with newly diagnosed and untreated NSCLC before and after induction chemotherapy. Skeletal muscle 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) uptake was measured from PET/CT images from a subset of patients (n=42). Comparisons of each metric before and after induction chemotherapy were conducted using the non-parametric Wilcoxon signed-rank test for paired data. The association between clinical factors and percentage change in muscle volume was examined using univariate linear regression models, with adjustment for baseline muscle volume.
RESULTS: Following induction chemotherapy, thoracic (-3.3%, p=0.0005) and lumbar (-2.6%, p=0.0101) skeletal muscle volume were reduced (adiposity remained unchanged). The proportion of skeletal muscle with a density <0 HU increased (7.9%, p<0.0001), reflecting a decrease in skeletal muscle density and skeletal muscle FDG uptake increased (10.4-31%, p<0.05). No imaging biomarkers were correlated with overall survival.
CONCLUSION: Changes in body composition can be measured from routine thoracic imaging. During chemotherapy skeletal muscle volume and metabolism are altered; however, there was no impact on survival in this retrospective series, and further validation in prospective, well-controlled studies are required.
引用
- Goncalves MD, Taylor S, Halpenny DF, et al. Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clin Radiol. 2018. PMID: 29317048. doi:10.1016/j.crad.2017.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。